Headache Disorders affect over

38 million people in the US and Canada

Current treatments are either ineffective, too expensive or present severe side effects



Pain Relievers



Neurolytics



CGRP Inhibitors



Natural Alternatives



Inhalational



Oral Preventative

Migraine Drug market

2021

$2.38B Dollars

Migraine market Forecast next 10 years

8.8% CAGR

Cluster Headache drug market 2022

$908M Dollars

Cluster Headache Forecast next 10 years

5.2% CAGR

At the intersection of emerging health science, technology and drug development

mature-businesswoman-working-at-office-e1678089661222.jpg

BlueThera is seeking to bring novel therapeutics to market leveraging the known benefits of cannabinoids and psilocybin in the treatment of primary headache disorders.

Our strategy incorporates natural extract API‘s, developed using proprietary extraction science & technology to achieve both efficacy and better tolerance compared to mono-molecular synthetic alternatives.

Drug Development Pipeline

Our drug candidates offer acute and preventative therapeutic options for chronic pain management associated with primary headache disorders

Discovery

Pre-Clinical

Phase 1

Phase 2/3

Approval

BioTheraMin™ Acute Migraine
BioTheraCinCH™ Preventative Cluster Headache
BioTheraCinMH™ Preventative Migraine

Development Platform and Technology

6500 sqft. GMP manufacturing facility with Health Canada licenses for:

Controlled Substance Dealers License

Cannabis Processing

Natural Health Products

4 Provisional Patents for Psilocybin formulations

1 Patent Application for novel natural psilocybin extraction process

3 Provisional Patents for Cannabinoid formulations

As of today there are no cannabinoid or psilocybin approved therapeutics for headache disorders

BlueThera is a Canadian based company that has a world class leadership team with deep experience in cannabis, natural health products, pharma, biotech and extraction technologies.